CVRx, Inc. (NASDAQ:CVRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Shares of CVRx, Inc. (NASDAQ:CVRX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $14.00.

Several analysts have recently commented on the stock. Piper Sandler decreased their price target on shares of CVRx from $20.00 to $12.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $11.00 price objective on shares of CVRx in a research note on Tuesday, August 5th. William Blair raised shares of CVRx to a "strong-buy" rating in a research note on Monday, July 7th. Finally, JPMorgan Chase & Co. reaffirmed an "underweight" rating and issued a $7.00 price objective (down from $15.00) on shares of CVRx in a research note on Friday, May 9th.

CVRx Price Performance

Shares of NASDAQ CVRX traded up $0.23 during mid-day trading on Tuesday, hitting $7.80. 302,546 shares of the stock were exchanged, compared to its average volume of 303,006. The company has a market cap of $203.97 million, a P/E ratio of -3.71 and a beta of 1.27. The stock's fifty day simple moving average is $7.09 and its two-hundred day simple moving average is $8.64. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99. CVRx has a twelve month low of $4.30 and a twelve month high of $18.55.

CVRx (NASDAQ:CVRX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.05). The firm had revenue of $13.59 million for the quarter, compared to analyst estimates of $13.22 million. CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%. CVRx has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts forecast that CVRx will post -1.91 EPS for the current fiscal year.

Hedge Funds Weigh In On CVRx

A number of hedge funds and other institutional investors have recently bought and sold shares of CVRX. Larson Financial Group LLC bought a new position in CVRx in the first quarter valued at approximately $28,000. Mount Lucas Management LP acquired a new stake in CVRx in the second quarter worth $30,000. Tower Research Capital LLC TRC raised its holdings in CVRx by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company's stock worth $49,000 after purchasing an additional 1,186 shares during the period. GAMMA Investing LLC raised its holdings in CVRx by 1,469.3% in the first quarter. GAMMA Investing LLC now owns 4,598 shares of the company's stock worth $56,000 after purchasing an additional 4,305 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in CVRx in the second quarter worth $59,000. 75.27% of the stock is owned by institutional investors.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.